

against HIV infection using an immunogen that will induce a cell-mediated immune response without inducing a humoral immune response, classified in class 424, subclass 188.1 and 208.1, and herein cancel claims 27-31 and 34-39.

AMENDMENTS

Please cancel claims 1, 11-16, 18, 19, 26-31 and 34-39 without prejudice.

Please enter the following amendments:

20. (Amended) The method of claim 17 wherein said mammal is a

B1 human.

REMARKS

Applicants had previously canceled claims 2-10 and 21-25 without prejudice in the paper filed on August 29, 2002. Applicants herein cancel claims 1, 11-16, 18, 19, 26-31 and 34-39 without prejudice. Upon entry of the above amendments claims 17, 20, 32 and 33 would be pending.

Claim 20 was amended to change its dependency to claim 17 rather than claim 18. Support for this subject matter is found, *inter alia*, in original claims 17, 18 and 20.

Applicants believe the amendment presents no new matter and respectfully request its entry.

CONCLUSION

In view of the foregoing, Applicants believe all claims now pending in this Application are in condition for examination.

Raoul E. Benveniste, *et al.*
Application No.: 09/769,223
Page 3

PATENT

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 925-472-5000.

Respectfully submitted,



Frank J. Mycroft
Reg. No. 46,946

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
FJM:mmm
WC 9051842 v1

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the claims:

Claims 1, 11-16, 18, 19, 26-31 and 34-39 have been canceled without prejudice.

Claim 20 has been amended as follows:

20. (Amended) The method of claim 17 [18] wherein said mammal is a human.

APPENDIX I

PENDING CLAIMS AFTER ENTRY OF THIS AMENDMENT

17 A method for vaccinating a human against a human immunodeficiency virus comprising the steps of:

i) selecting an immunogen competent to induce a protective immune response in said human against said human immunodeficiency virus, and

ii) administering an effective amount of said immunogen to said human sufficient to induce a cell mediated response against said human immunodeficiency virus but below the amount necessary to induce a humoral response.

LAG/FEL 20. (Amended) The method of claim 17 wherein said mammal is a human.

FEL 32. (New) The method of claim 31, wherein said immunogen has been inactivated by removing a sufficient portion of its genetic material so as to render it incapable of replicating.

LAG 33. (New) The method of claim 32, wherein the genetic material removed from said human immunodeficiency virus is a portion of a gene coding for a gag nucleocapsid protein.

CMI BUT
NOT HI;
GRAMS UNUSUAL

ORIGINAL

itd

22, 26, 22, 19, 15, 10, 9, 1
34, 30, 27, 25, 17, 14
8, 2
8, 22, 1

6121021